FLT3 inhibitors for acute myeloid leukemia: A review of their efficacy and mechanisms of resistance

Michael R. Grunwald, Mark J. Levis

Research output: Contribution to journalReview articlepeer-review

Abstract

Since the Food and Drug Administration approval of imatinib for treatment of chronic myeloid leukemia in 2001, tyrosine kinase inhibitors (TKIs) have become a mainstay in the care of many malignancies. In acute myeloid leukemia (AML), activating mutations in the FMS-like tyrosine kinase 3 (FLT3) gene result in survival and proliferation of leukemic blasts and are associated with adverse prognosis. Therefore, the FLT3 receptor is an appealing target for inhibition. Multiple small molecule TKIs are currently in development for FLT3-mutated AML, and agents are beginning to show promising efficacy. In other malignancies, the development of resistance to TKIs during the course of therapy has proven to be a challenge, and thus far, in clinical trials of FLT3 TKIs, resistance to inhibition represents a significant barrier to successful FLT3 inhibition. Understanding the mechanisms of resistance and overcoming these obstacles to target inhibition will be central to the success of these agents.

Original languageEnglish (US)
Pages (from-to)683-694
Number of pages12
JournalInternational journal of hematology
Volume97
Issue number6
DOIs
StatePublished - Jun 1 2013

Keywords

  • Acute myeloid leukemia (AML)
  • FLT3
  • Tyrosine kinase inhibitor (TKI)

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'FLT3 inhibitors for acute myeloid leukemia: A review of their efficacy and mechanisms of resistance'. Together they form a unique fingerprint.

Cite this